The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United Kingdom

Transplantation

Volumn 86, Issue 8, 2008, Pages 1035-1042

  Shah, Sapna ^a   Collett, Dave ^b   Johnson, Rachel ^b   Raftery, Martin ^a   Rudge, Chris ^b   Yaqoob, Mohammad M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b United Kingdom Transplant   (United Kingdom)

Author keywords

Azathioprine; Dose; Mycophenolate mofetil; Outcome; Renal transplant

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED KINGDOM; ALLOTRANSPLANTATION; COMPARATIVE STUDY; DOSE RESPONSE; GRAFT REJECTION; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 55949085726     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318186dc81     Document Type: Article

References (25)

1. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215.
2. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181.
3. Placebo-controlled study of mycophenolate mofetil combined with cyclo-sporin and corticosteroids for prevention of acute rejection. European My-cophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321.
4. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029.
5. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
6. Halloran P, Mathew T, TomlanovichS, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39.
7. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus aza-thioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. Lancet 2004; 364: 503.
8. Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: The MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18: 1973.
9. Kahu J, Kyllonen L, Salmela K.Impact of mycophenolate mofetil intolerance on early results of kidney transplantation. Transplant Proc 2005; 37: 3276.
10. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycopheno-late mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779.
11. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
12. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
13. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
14. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7: 2704.
15. Shah S, Collett D, Johnson R, et al. Long-term graft outcome with mycophenolate mofetil and azathioprine: A paired kidney analysis. Transplantation 2006; 82: 1634.
16. Levey AS, Greene T, Schluchter MD, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 1159.
17. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005; 79: 466.
18. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176: 640.
19. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. JClin Invest 2003; 111: 1133.
20. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999; 34: 296.
21. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450.
22. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672.
23. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
24. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
25. Van Gelder T, Silva HT, Fijter H, et al. A prospective, randomized study comparing fixed dose vs concentration controlled MMF regimes for de novo patients following renal transplantation (The FDCC trial). Transplantation 2006; 82: 344.